Robert W McGarrah1,2, Jacob P Kelly3,2,4, Damian M Craig2, Carol Haynes2, Ryan C Jessee5, Kim M Huffman2,5, William E Kraus3,2, Svati H Shah3,2,4. 1. Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC; robert.mcgarrah@dm.duke.edu. 2. Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC. 3. Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC. 4. Duke Clinical Research Institute, Duke University, Durham, NC. 5. Division of Rheumatology, Department of Medicine, Duke University School of Medicine, Durham, NC.
Abstract
BACKGROUND: Evidence suggests that systemic inflammation may adversely impact HDL function. In this study we sought to evaluate the independent and incremental predictive performance of GlycA-a novel serum inflammatory biomarker that is an aggregate measure of enzymatically glycosylated acute phase proteins-and HDL subclasses on adverse events in a retrospective observational study of a secondary prevention population and to understand a priori defined potential interactions between GlycA and HDL subclasses. METHODS: GlycA and HDL subclasses were measured using proton nuclear magnetic resonance spectroscopy in 7617 individuals in the CATHGEN (CATHeterization GENetics) cardiac catheterization biorepository. RESULTS: GlycA was associated with presence [odds ratio (OR) 1.07 (1.02-1.13), P = 0.01] and extent [OR 1.08 (1.03, 1.12) P < 0.0005] of coronary artery disease and with all-cause mortality [hazard ratio (HR) 1.34 (1.29-1.39), P < 0.0001], cardiovascular mortality [1.37 (1.30-1.45), P < 0.0001] and noncardiovascular mortality [1.46 (1.39-1.54) P < 0.0001] in models adjusted for 10 cardiovascular risk factors. GlycA and smaller HDL subclasses had independent but opposite effects on mortality risk prediction, with smaller HDL subclasses being protective [HR 0.69 (0.66-0.72), P < 0.0001]. There was an interaction between GlycA and smaller HDL subclasses-increasing GlycA concentrations attenuated the inverse association of smaller HDL subclasses with mortality. Adding GlycA and smaller HDL subclasses into the GRACE (Global Registry of Acute Coronary Events) and Framingham Heart Study Risk Scores improved mortality risk prediction, discrimination and reclassification. CONCLUSIONS: These findings highlight the interaction of systemic inflammation and HDL with clinical outcomes and may increase precision for clinical risk assessment in secondary prevention populations.
BACKGROUND: Evidence suggests that systemic inflammation may adversely impact HDL function. In this study we sought to evaluate the independent and incremental predictive performance of GlycA-a novel serum inflammatory biomarker that is an aggregate measure of enzymatically glycosylated acute phase proteins-and HDL subclasses on adverse events in a retrospective observational study of a secondary prevention population and to understand a priori defined potential interactions between GlycA and HDL subclasses. METHODS:GlycA and HDL subclasses were measured using proton nuclear magnetic resonance spectroscopy in 7617 individuals in the CATHGEN (CATHeterization GENetics) cardiac catheterization biorepository. RESULTS:GlycA was associated with presence [odds ratio (OR) 1.07 (1.02-1.13), P = 0.01] and extent [OR 1.08 (1.03, 1.12) P < 0.0005] of coronary artery disease and with all-cause mortality [hazard ratio (HR) 1.34 (1.29-1.39), P < 0.0001], cardiovascular mortality [1.37 (1.30-1.45), P < 0.0001] and noncardiovascular mortality [1.46 (1.39-1.54) P < 0.0001] in models adjusted for 10 cardiovascular risk factors. GlycA and smaller HDL subclasses had independent but opposite effects on mortality risk prediction, with smaller HDL subclasses being protective [HR 0.69 (0.66-0.72), P < 0.0001]. There was an interaction between GlycA and smaller HDL subclasses-increasing GlycA concentrations attenuated the inverse association of smaller HDL subclasses with mortality. Adding GlycA and smaller HDL subclasses into the GRACE (Global Registry of Acute Coronary Events) and Framingham Heart Study Risk Scores improved mortality risk prediction, discrimination and reclassification. CONCLUSIONS: These findings highlight the interaction of systemic inflammation and HDL with clinical outcomes and may increase precision for clinical risk assessment in secondary prevention populations.
Authors: William E Kraus; Christopher B Granger; Michael H Sketch; Mark P Donahue; Geoffrey S Ginsburg; Elizabeth R Hauser; Carol Haynes; L Kristin Newby; Melissa Hurdle; Z Elaine Dowdy; Svati H Shah Journal: J Cardiovasc Transl Res Date: 2015-08-14 Impact factor: 4.132
Authors: Svati H Shah; James R Bain; Michael J Muehlbauer; Robert D Stevens; David R Crosslin; Carol Haynes; Jennifer Dungan; L Kristin Newby; Elizabeth R Hauser; Geoffrey S Ginsburg; Christopher B Newgard; William E Kraus Journal: Circ Cardiovasc Genet Date: 2010-02-19
Authors: Akintunde O Akinkuolie; Aruna D Pradhan; Julie E Buring; Paul M Ridker; Samia Mora Journal: Arterioscler Thromb Vasc Biol Date: 2015-04-23 Impact factor: 8.311
Authors: Keith A A Fox; Omar H Dabbous; Robert J Goldberg; Karen S Pieper; Kim A Eagle; Frans Van de Werf; Alvaro Avezum; Shaun G Goodman; Marcus D Flather; Frederick A Anderson; Christopher B Granger Journal: BMJ Date: 2006-10-10
Authors: James D Otvos; Irina Shalaurova; Justyna Wolak-Dinsmore; Margery A Connelly; Rachel H Mackey; James H Stein; Russell P Tracy Journal: Clin Chem Date: 2015-03-16 Impact factor: 8.327
Authors: Jincui Huang; Hyeyoung Lee; Angela M Zivkovic; Jennifer T Smilowitz; Nancy Rivera; J Bruce German; Carlito B Lebrilla Journal: J Proteome Res Date: 2014-01-21 Impact factor: 4.466
Authors: James D Otvos; John R Guyton; Margery A Connelly; Sydney Akapame; Vera Bittner; Steven L Kopecky; Megan Lacy; Santica M Marcovina; Joseph B Muhlestein; William E Boden Journal: J Clin Lipidol Date: 2018-01-12 Impact factor: 4.766
Authors: Angelica Ezeigwe; Oluwaseun E Fashanu; Di Zhao; Matthew J Budoff; James D Otvos; Isac C Thomas; Samia Mora; Martin Tibuakuu; Erin D Michos Journal: Atherosclerosis Date: 2019-01-24 Impact factor: 5.162
Authors: Andrew P Demidowich; Anna Wolska; Sierra R Wilson; Jordan A Levine; Alexander V Sorokin; Sheila M Brady; Alan T Remaley; Jack A Yanovski Journal: J Clin Lipidol Date: 2019-10-22 Impact factor: 4.766
Authors: Shafqat Ahmad; Samia Mora; Paul W Franks; Marju Orho-Melander; Paul M Ridker; Frank B Hu; Daniel I Chasman Journal: Clin Chem Date: 2017-11-02 Impact factor: 8.327
Authors: Robert W McGarrah; Scott B Crown; Guo-Fang Zhang; Svati H Shah; Christopher B Newgard Journal: Circ Res Date: 2018-04-27 Impact factor: 17.367
Authors: Jacob L Barber; William E Kraus; Timothy S Church; James M Hagberg; Paul D Thompson; David B Bartlett; Michael W Beets; Conrad P Earnest; Kim M Huffman; Rian Q Landers-Ramos; Arthur S Leon; D C Rao; Richard L Seip; James S Skinner; Cris A Slentz; Kenneth R Wilund; Claude Bouchard; Mark A Sarzynski Journal: Atherosclerosis Date: 2018-07-26 Impact factor: 5.162